LeMaitre Vascular (NASDAQ:LMAT) Posts Earnings Results, Beats Estimates By $0.05 EPS

LeMaitre Vascular (NASDAQ:LMAT) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05, Briefing.com reports. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year.

LeMaitre Vascular Trading Up 7.3 %

LMAT traded up $6.49 during midday trading on Friday, hitting $94.88. 343,615 shares of the company were exchanged, compared to its average volume of 123,348. The company’s 50 day simple moving average is $89.53 and its 200 day simple moving average is $82.77. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of 59.86, a price-to-earnings-growth ratio of 2.33 and a beta of 0.88. LeMaitre Vascular has a 1-year low of $45.96 and a 1-year high of $101.67.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LMAT shares. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Barrington Research lifted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday. JMP Securities upped their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.